UncategorizedAbbVie reports promising outpatient potential for epcoritamab in relapsed/refractory DLBCL – Longevity.Technology Empower Meds / September 4, 2025
UncategorizedC2N Diagnostics to expand St. Louis headquarters amid global Alzheimer’s need – Longevity.Technology Empower Meds / September 4, 2025
UncategorizedProMIS Neurosciences advances to final dose cohort in Alzheimer’s trial – Longevity.Technology Empower Meds / September 4, 2025
UncategorizedHaut.AI collaborates with Neutrogena on refreshed Neutrogena Skin360 – Longevity.Technology Empower Meds / September 4, 2025
UncategorizedBuck Institute research ties gut immune activity to Alzheimer’s Empower Meds / September 4, 2025
UncategorizedMytos inks multiple cell therapy manufacturing partnerships – Longevity.Technology Empower Meds / September 3, 2025
UncategorizedNanoscope strengthens global regulatory pathways for MCO-010 – Longevity.Technology Empower Meds / September 3, 2025
UncategorizedFirst patient dosed in Citryll’s Phase IIa trial of CIT-013 in RA – Longevity.Technology Empower Meds / September 3, 2025
